Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 20,598 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Terminated Phase 1 Interventional

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

NCT01643603
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Myeloid Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Lymphoid Leukemia
Interventions
Dasatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 19, 2026, 11:52 PM EDT
Recruiting Phase 2 Interventional

Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis

NCT04380740
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Placebo, Abatacept
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 19, 2026, 11:52 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma

NCT00002676
View directory record Official record
Conditions
Lymphoma
Interventions
carmustine, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, methotrexate, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
21
States / cities
Scottsdale, Arizona • Denver, Colorado • Peoria, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 19, 2026, 11:52 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

NCT02269917
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1
Interventions
D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
38
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Oct 19, 2026, 11:52 PM EDT
Recruiting Not applicable Interventional

Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature

NCT07386340
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitoring System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 19, 2026, 11:52 PM EDT
Completed No phase listed Observational

An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers

NCT00005570
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic, Immune Thrombocytopenic Purpura
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 19, 2026, 11:52 PM EDT
Completed No phase listed Observational

Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis

NCT02308670
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 19, 2026, 11:52 PM EDT
Completed Phase 2 Interventional

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

NCT00038376
View directory record Official record
Conditions
Lymphoma, T-Cell, Mycosis Fungoides, Hematologic Neoplasms
Interventions
Isotretinoin (Accutane), Interferon Alpha
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 19, 2026, 11:52 PM EDT
Terminated Phase 2Phase 3 Interventional

Lamictal in the Treatment of Post-Herpetic Neuralgia

NCT00295776
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
Lamictal in the treatment of Post-Herpetic Neuralgia
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 85 Years
Timeline
Started 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 19, 2026, 11:52 PM EDT
Completed Not applicable Interventional

The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients

NCT00000861
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
1,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
14
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 19, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet

NCT00984971
View directory record Official record
Conditions
HIV Prevention, HIV Infections
Interventions
Tenofovir, HEC Placebo, Open label tenofovir tablet
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2015 · Synced Oct 19, 2026, 11:52 PM EDT
Completed Phase 4 Interventional Results available

Anti-TNF Agents for the Treatment of Rheumatoid Arthritis

NCT00837434
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Adalimumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 19, 2026, 11:52 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of SPC3 in HIV-1 Infected Patients

NCT00002363
View directory record Official record
Conditions
HIV Infections
Interventions
Peptide Construction 3, Synthetic
Drug
Lead sponsor
Columbia Research Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 11:52 PM EDT
Terminated Phase 2 Interventional Results available

MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma

NCT03218163
View directory record Official record
Conditions
Multiple Myeloma
Interventions
MEDI-551 Maintenance
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 19, 2026, 11:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hispanic Men Building Respect Education and Safety/ HoMBRES Manteniendo Respeto, Educacion y Seguridad.

NCT03730987
View directory record Official record
Conditions
Substance Abuse, Domestic Violence, HIV/AIDS
Interventions
HoMBReS intervention, Families Talking Together (FTT), Diabetes Prevention Intervention
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Male only
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 19, 2026, 11:52 PM EDT
Terminated Phase 2 Interventional Results available

Alemtuzumab and Pentostatin In T-cell Neoplasms

NCT00453193
View directory record Official record
Conditions
Lymphoma, Leukemia
Interventions
Pentostatin, Alemtuzumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 19, 2026, 11:52 PM EDT
Terminated Phase 1 Interventional

Melphalan With BBBD in Treating Patients With Brain Malignancies

NCT00253721
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer
Interventions
Melphalan
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 19, 2026, 11:52 PM EDT
Completed Not applicable Interventional

Coping and Adjusting to Living With Multiple Sclerosis

NCT04300816
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
CBT for Uncertainty Tolerance, Traditional CBT
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 19, 2026, 11:52 PM EDT
Completed Phase 1 Interventional

Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma

NCT00317798
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
anti-thymocyte globulin, sirolimus
Biological · Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2011 · Synced Oct 19, 2026, 11:52 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT00873093
View directory record Official record
Conditions
B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions
L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, cytarabine, prednisone, bortezomib, pegaspargase, methotrexate, etoposide phosphate, cyclophosphamide, filgrastim, leucovorin calcium, laboratory biomarker analysis, High Dose MTX
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
157
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 124 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 19, 2026, 11:52 PM EDT
Terminated Phase 1 Interventional

Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

NCT03379493
View directory record Official record
Conditions
Lymphomas Non-Hodgkin's B-Cell
Interventions
ET190L1 ARTEMIS™ T cells
Biological
Lead sponsor
Eureka Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 19, 2026, 11:52 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Genetics of Asthma - Bronchoscopy Studies

NCT00644514
View directory record Official record
Conditions
Atopic Asthma, Healthy
Interventions
Endotoxin - lipopolysaccharide (LPS)
Biological
Lead sponsor
John Sundy
Other
Eligibility
18 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 19, 2026, 11:52 PM EDT
Completed Phase 1 Interventional

BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

NCT00346255
View directory record Official record
Conditions
Multiple Myeloma
Interventions
BB-10901
Drug
Lead sponsor
ImmunoGen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Oct 19, 2026, 11:52 PM EDT
Completed Phase 2 Interventional Results available

Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis

NCT02024555
View directory record Official record
Conditions
Sarcoidosis; Antimycobacterial Therapy
Interventions
Levofloxacin, Ethambutol, Azithromycin, Rifampin, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Albany, New York • Cincinnati, Ohio • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 19, 2026, 11:52 PM EDT